Analyst Commentary Highlights Growth Prospects and Risks Following Alkermes Acquisition and Updated Valuation

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

31 Aug 24

Updated

06 Dec 25

Views

199

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-6.4%

7D

-2.4%

Loading

1Y

-6.4%

7D

-2.4%

You can edit this narrative until Dec 7 12:10 AM. Then, changes will post as Updates.

Author's Valuation

US$43.8836.6% undervalued

AnalystConsensusTarget Fair Value

Shared on 06 Dec 25

ALKS: Sleep Medicine Acquisition Will Drive Future Orexin Opportunity Upside

Analysts modestly lift their price target on Alkermes, reflecting confidence that the strategically priced Avadel acquisition, solid narcolepsy data and an underappreciated orexin class opportunity can drive upside, despite only incremental changes to long term growth and profitability assumptions. Analyst Commentary Street views on Alkermes remain mixed, with a generally constructive stance on long term positioning in sleep medicine and orexin agonists, tempered by questions around differentiation, safety profile and competitive intensity.

Shared on 21 Nov 25

Fair value Decreased 0.28%

ALKS: Sleep Medicine Acquisition Will Drive Momentum After Narcolepsy Study Results

Analysts have slightly reduced their price target for Alkermes to $43.88 from $44, reflecting tempered revenue growth assumptions and competitive data from recent narcolepsy studies. Analyst Commentary Analyst sentiment regarding Alkermes remains divided following the latest developments in its narcolepsy franchise and pending acquisition of Avadel Pharmaceuticals.

Shared on 06 Nov 25

Fair value Increased 3.45%

ALKS: Clinical Progress In Narcolepsy Will Drive Share Momentum This Fall

Analysts have raised their fair value estimate for Alkermes from $42.53 to $44.00 per share. They cite stronger revenue growth forecasts and recent clinical and strategic updates, which improve the company's near- and mid-term outlook.

Shared on 22 Oct 25

Fair value Increased 2.27%

Alkermes' analyst price target was raised approximately $0.95 to $42.53 per share, as analysts point to improved profit margin outlook and the anticipated benefits from its Avadel Pharmaceuticals acquisition. These factors are expected to support both near- and mid-term growth.

Shared on 07 May 25

Fair value Increased 15%

Shared on 19 Mar 25

Fair value Decreased 3.70%

AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.

Shared on 11 Mar 25

Fair value Decreased 7.34%

AnalystConsensusTarget has increased revenue growth from -1.3% to -2.7% and decreased profit margin from 15.5% to 13.9%.

AnalystConsensusTarget Fair Value

US$43.88

36.6% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

8.94%

Biotech revenue growth rate

9.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.43%

Calculation

US$407.38m

Earnings '28

x

22.96x

PE Ratio '28

=

US$9.35b

Market Cap '28

US$9.35b

Market Cap '28

/

172.86m

No. shares '28

=

US$54.11

Share Price '28

US$54.11 Share Price '28

Discounted to 2025 @ 7.42% p.a.

=

US$43.66

Fair Value '25